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ABSTRACT 
Given the fact that amorphous solid dispersions (ASD) have been one of the most popular 
formulation strategies to address the issue of inadequate aqueous solubility for small molecules, 
it is of particular interest to control crystal growth from supersaturated solution in order to 
maximize the extent of oral absorption of therapeutic agents. Recently, bile salts have been 
shown to delay crystallization of poorly soluble compounds. In this study, an in-situ common 
history seeding method was proposed to provide seeds that better mimic crystals formed from 
supersaturated solutions. The effectiveness of both monomeric and miceller biorelevent bile salts 
on solution crystal growth and secondary nucleation of telaprevir was then examined. Most bile 
salts investigated in this study exhibit growth inhibition properties. The extent of growth 
inhibition, however, various with structural difference amongst the bile salts and their 
aggregation level.  
 
 
 
 
 
 
 
 
 
INTRODUCTION 
Controlled crystallization with additives has been of great interests to the pharmaceutical 
industry. Due to the increased number of poorly soluble compound in the drug developmental 
pipeline, contemporary formulation strategies often involve implementing a higher energy form 
of active pharmaceutical ingredients (APIs). Take amorphous solid dispersion for example, the 
amorphous solids and the dissolved solution improve the extent of oral absorption by providing 
drug transport with a higher concentration gradient across the membrane.
1-3
 However, the 
inhered crystallization tendency of these high energy forms of API often imperils the stability 
and performance of the formulations.
4
  Employing foreign components to interrupt the 
crystallization process thus become an answer to maintaining solubility advantages of these 
formulations.
5
 
Solution crystallization consists of two major kinetic events: nucleation and crystal 
growth. Nucleation take place when a supersaturated system overcomes the free energy barrier 
for critical nucleus formation
6
, following by a consumption of molecularly dissolved solute due 
to new crystalline matter formation. Current research mostly focus on the impact of additives on 
nucleation. For instance, polymers are well known nucleation inhibitors for APIs,
7-10
 while 
surfactants on the other hands are found to promote nucleation
11
. Besides the commonly 
employed excipients in commercial formulation, bile salts, the endogenous surfactant exist in 
human intestinal fluids, has been shown to inhibit nucleation of a wide variety of structurally 
diverse APIs
11-13
[cite manuscript#2]. Meanwhile, there has been rising interests in controlled 
crystal growth in the past decade. Owing to the instable nature of amorphous formulations, 
thereÕs a high chance of crystalline seeds forming during formulation, manufacturing, storage or 
even upon drug administration. When crystal seeds presence, the lower energy barrier for kinetic 
events such as secondary nucleation and crystal growth facilitates supersaturation consumption, 
thus deplete the enhanced solubility advantage. The ability to control crystal growth, therefore, 
ensure a longer oral absorption time frame as the consume rate of molecularly dissolved solute 
may be slowed down.  
It is widely accepted that foreign species such as additives can alter crystal growth 
kinetics by adsorbing to growth sites and acting as a mechanical barrier.
6, 14
 Polymeric additives 
are known as effective growth inhibitors for poorly soluble compounds. Some of the key factors 
found to affect the extent of growth inhibition are the hydrophobic interactions between polymer 
and drug
15-18
,  polymer conformation upon surface absoption,
19, 20
 ability to form hydrogen 
bonding between polymer and drug,
21, 22
 as well as seed preparation.
23
 On the other hand, it has 
been demonstrated that surfactants can promote crystal growth, and negate the inhibitory impact 
of polymers.
23, 24
 Thus far, the impact of bile salts on drug crystallization kinetics has not been 
explored in detail. However, this is an important area of research given the inevitable encounter 
of supersaturating dosage forms and these endogenous surfactants during in vitro dissolution 
testing and in vivo. In our previous study, it was observed that all biorelevant bile salts 
effectively slow down formation of crystals from both homogenous supersaturated telaprevir 
solutions and highly supersaturated telaprevir solutions containing a second phase. Monomeric 
bile salts were found to be effective inhibitors, while the presence of bile salt micelles opposed 
the monomeric inhibitory effect for some of bile salts[cite manuscript#2]. In addition, the 
preliminary results reveal the potential of bile salts as crystal growth inhibitors. This current 
study builds upon our knowledge of the impact of bile salts on telparevir solution 
thermodynamics[cite M1] and solution crystallization[cite M2], and a systematic evaluation of 
both monomeric and miceller bile salts as crystal growth inhibitors was carried out by 
performing seeded desupersaturation experiments at the same activity-based supersaturation in 
the presence of six taurine/glycine conjugated dihydroxy (STDC, SGDC, STCDC, and SGCDC) 
and trihydroxy (STC and SGC) bile salts. 
MATERIALS  
 Telaprevir was obtained from Attix Pharmaceuticals (Toronto, Ontario, Canada) and 
ChemShuttle (CA). Hydroxypropyl methyl cellulose acetate succinate grade AS-MF (HPMCAS-
MF) was obtained from Shin Etsu Chemical Co., Ltd (Tokyo, Japan). Sodium taurocholate 
(practical grade, MP Biomedicals, LLC, OH), sodium glycocholate (≥99%, Chem-Impex IntÕl. 
Inc., IL), sodium taurodeoxycholate (≥97%, Chem-Impex IntÕl. Inc., IL), sodium 
glycodeoxycholate (≥97%, Sigma, MO), sodium taurochenodeoxycholate (98%, Sinova Inc., 
MD) and sodium glycochenodeoxycholate (≥99%, Chem-Impex IntÕl. Inc., IL) were used as 
received. Molecular structures of telaprevir and the six bile salts are shown in Figure 1 and Table 
1. A regenerated cellulose membrane with a molecular weight cutoff (MWCO) of 6-8k Da was 
acquired from Spectrum Laboratories, Inc. (Rancho Dominguez, CA). The aqueous media used 
in all experiments was 50mM pH 6.5 sodium phosphate buffer. 
METHODS  
In-situ Common History Seeding and Mass Growth Rate Measurements. 
 Crystal growth is sensitive to seed properties. To better mimic how nuclei grow when 
they first form in supersaturated solution, an in-situ common history seeding method was 
implemented to provide suitable seeds for telaprevir crystal growth rate measurements (Figure 2). 
Supersaturated telaprevir solutions were prepared by titrating concentrated methanolic telaprevir 
stock solution (12 mg/mL) to 50mL of 50 mM pH 6.5 sodium phosphate buffer to achieved 
telaprevir concentration of 60µg/mL. The supersaturated solution was then stirred at 300 rpm at 
37 ¡C for 6 hours to allow crystallization taking place.  After fixed 6 hour seeding period, 
telaprevir solution concentration was observed to decrease back to it crystalline solubility, and 
supersaturation in solution was regenerated by adding methanolic telaprevir stock solution 
according to the activity-based supersaturation calibration curves shown in our previous 
study[cite manuscript#2] to achieve different initial supersaturation levels. The corresponding 
concentrations are listed in Table 2. For experiments with bile salts, bile salts (1.86mM or 12mM 
concentration) were added to the seed solution and allow to equilibrium prior to supersaturation 
regeneration. The crystal growth rate of telaprevir were then determined by measuring the rate of 
desupersaturation in the seeded solution. The initial slope of the desupersaturation curve (first 30 
minutes for δ=2.7 and first 10 minutes for higher supersaturation levels) after supersaturation 
regeneration was determined as the desupersaturation rate R.  The concentration change of 
telaprevir solution during the seeding process, as well as the crystal growth period were was 
monitored by a SI Photonics UV/vis spectrometer (Tuscon, Arizona), fiber optically coupled 
with a 1 cm or 0.5cm path length dip probe, at a wavelength of 270 nm. Wavelength scan (200-
450nm) were perform at 1 minute interval for 16 hours. Second derivatives of the UV spectrum 
were taken using SIMCA 13.0.3 software (Umetrics Inc., Umea Sweden) for calibrations and 
sample acquisitions to mitigate potential particle scattering effect caused by seed crystals and 
bile salt micelles. The standard curve presented good linearity (R
2
> 0.99) over the relevant 
concentration range. Solution turbidity was as well recorded by monitoring change in extinction 
at 370nm wavelength, where telaprevir have no absorbance, as an indication for secondary 
nucleation.
17
  
Residual Supersaturation Determination. 
 A side-by-side diffusion cell (PermeGear, Inc. Hellertown, PA) was used to evaluate 
the residual supersaturation level of telaprevir crystallized solutions in the absence and presence 
of different bile salts (at 1.86 mM or 12 mM bile salt concentrations). The basic concepts were as 
described in the previous studies.[cite M#1 and M#2] The ratio of solute mass flow rate in the 
solution of interest (F) to the mass flow rate of the corresponding standard state system (F¡), 
solute in a solution in equilibrium with crystalline state in this study, yields the fundamental 
supersaturation δ:  
 
!
!!
!
!
!!
! !! (1) 
where ! is the solute activity in the solution of interest, and  !! is the solute activity at standard 
state. With the mass flow rate data and the previously established calibration curve[cite 
manuscript#1], residual supersaturation level of telaprevir solution after 15 hour growth can be 
determined from Equation (1).  
Seed Crystal Morphology Characterization. 
The scanning electron microscopy (SEM) was used to reveal the morphology of telaprevir 
crystals prepared by the in-situ common history seeding method as well as the ones obtained 
from suppliers. For telaprevir crystals prepared by in-situ common history seeding method, small 
amount of liquid samples (approximately 10µL) were extracted from the seeded solution after 6 
hour seeding time, and deposit on glass coverslips and placed into the vacuum oven for a week 
prior to observation to remove any remaining liquid. The dried samples were sputter-coated with 
platinum for 60 seconds, and imaged with a FEI NOVA nanoSEM field emission SEM 
(Hillsboro, Oregon), using an Everhart−Thornley detector (ETD) and through-the-lens detector 
(TLD). The parameters were 5 kV accelerating voltage, about 5 mm working distance, beam 
spot size of 3, 30 µm aperture, and magnifications in the 5000−30000× range. 
Zeta Potential Measurements. 
 The zeta potentials of telaprevir seed crystals in solutions in the presence of 
monomeric bile salts were measured using a Nano-Zetasizer (Nano ZS, Malvern, Westborough, 
MA). Telaprevir seed crystals were obtained by titrating concentrated methanolic telaprevir stock 
solution (12 mg/mL) into 10mL of 50 mM pH 6.5 sodium phosphate buffer with 1.86mM bile 
salts. The solutions were stirred at 300rpm at 37¡C, allowing crystallization to take place, and the 
seed crystals were continuously stirred overnight for equilibrium. 1.86mM of bile salts were 
added to the stirred seed crystal solution 30 minutes prior to zeta potential measurements. The 
zeta potentials of telaprevir seed crystals with no bile salt were also measured for reference.  
RESULTS AND DISCUSSIONS 
Common History Seed Crystals and Crystal Growth rates 
Seeding has been a crucial step to crystallization in the pharmaceutical industry as it 
strongly dictates the final product properties. It has been demonstrated that seed crystals prepared 
in different environments leads to different abilities to subsequently grow
23
. To prepared seeds 
that better imitate crystal growth after direct nucleation from supersaturated solutions, we 
proposed an in-situ common history seeding methods. The concept of common history seed was 
first introduced by White et al., in which the authors described common history (CH) seed as a 
batch of crystal that were nucleated at the same time and then experience the same growth 
history, i.e. under same temperature, same supersaturation and for the same length of time.
25
 For 
CH seed, it is reported that the shape of the crystal size distribution will be maintained 
throughout the crystallization process and as these seed crystal grows.
26, 27
  
In this study, all seeds crystals were prepared by direct nucleation from telaprevir 
supersaturated solutions, with an initial concentration of 60µg/mL, at 37¡C for 6 hours. After the 
fixed seeding period, telaprevir solution concentrations were observed to be around telaprevir 
crystalline solubility. That is, same seed loading (mass-wise) were provided with our proposed 
seeding method. Figure 3 shows the desupersaturation profile of telaprevir crystals in the absence 
of bile salts after supersaturation was regenerated. The desupersaturation rate under three 
different supersaturation levels is 5.4±0.8µg/min, 58.6±2.2µg/min and 89.2±7.6µg/min, 
respectively. The high reproducibility of the desupersaturation curves imply our good control 
over seed properties with the proposed method. The impact of preparation methods on seed 
properties is revealed in Figure 4. It should be noted that control experiment (in-situ seeding in 
water) was shown as well to confirm that the observed crystals were not from buffer salts. It is 
evident that the primary particle size of crystal obtained from supplier is larger than the ones 
prepared by the in-situ CH seeding method and the shape are different, which can potentially 
affect crystal growth behavior.  In addition, we observed that telaprevir seeds prepared by the in-
situ CH method tend to form bouquet-like aggregates, which is difficult to evaluate crystal 
growth rates by performing image analysis for individual crystals. Therefore, crystal growth rates 
in this study were determined by the monitoring the change in solution concentration, which is 
directly related to the mass deposition on existing seed crystals.
6
 
Amongst the three supersaturation levels performed in this study, there was no 
observable change in turbidity measurement for experiments with initial supersaturation level 
δ=2.4. That is, there was no evidence of significant secondary nucleation for these systems, and 
the desupersaturation can be assumed to be mainly due to the bulk crystal growth of the seed 
crystals. On the other hand, there were detectable increase in turbidity measurements for 
experiments at higher supersaturation levels (δ=7.9 and 12.5), indicating the occurrence of 
secondary nucleation. Therefore, crystal growth rates in this study were determined from the 
desupersaturation rates at supersaturation level δ=2.4. The desupersaturation rates at higher 
supersaturation levels were as well investigated to evaluate the impact of bile salts on secondary 
nucleation kinetics. 
Crystal Growth and Desupersaturation Rates of Telaprevir in the Presence of Bile Salts 
The impact of bile salts on telaprevir desupersaturation rate was investigated at three 
different initial supersaturation ratio. At supersaturation level δ=2.4, where crystal growth being 
the dominating kinetics, the effectiveness of bile salts in inhibiting crystal growth EG was 
estimated using the following equation: 
 !! !
!!
!
!! (2) 
where R0 and R are the initial desupersaturation rate in the absence and presence of bile salt, 
respectively. Bile salts with EG >1 were considered to be effective crystal growth inhibitors. At 
higher supersaturation levels δ=7.9 and 12.5, where both crystal growth and secondary 
nucleation can take place, the effectiveness of bile salts in inhibiting the combined kinetics Ec 
was then estimated using the Equation (3). Bile salts with EC >1 were considered to be effective 
inhibitors for the combined kinetics. 
 !! !
!!
!
 (3) 
Figures 5 shows a comparison of effective EG and Ec of bile salts at 1.86mM and 12mM 
concentration, respectively. As discussed in the previous studies,[cite M#1 and 2], the majority 
of bile salts in solution at a concentration of 1.86mM are in monomeric form, and micellar bile 
salts are most likely the dominant species at a bile salt concentration of 12mM. As shown in 
Figure 5(a), the biorelevant bile salts show different extent in inhibiting telaprevir crystal growth. 
Except for STDC showing minimal effectiveness, four out of five investigated bile salts are 
effective at 1.86mM concentration (monomer). The EG value for monomeric STC, SGC, and 
SGDC ranges around 1.4-3.2, which is comparable to reported values of commercially available 
polymers to poorly soluble drugs.
17, 28
 Interestingly, monomeric STCDC appears to be the 
extreme case, where no desupersaturation was observed during the experiments. In other words, 
monomeric STCDC blocked telaprevir crystal growth. Similar observations i.e. complete 
suppress of crystal growth are commonly encountered in crystallization with impurities or 
additives.
29-31
 As bile salt concentration increased to 12mM, comparable crystal growth 
inhibition was observed for all investigated bile salts, except for STCDC. This observation 
suggested that the presence of bile salt micelles have minimal impact on crystal growth 
inhibition ability for monomeric STC, SGC, STDC, and SGDC. However, STCDC micelles 
show opposed effect to its monomers. At a much higher supersaturation level δ=12.5, similar 
patterns in terms of the extent of inhibition amongst the investigated bile salts were observed 
(Figure 5(b)). Monomeric STCDC remained the most effective inhibitor for combined kinetics of 
crystal growth and secondary nucleation (no desupersaturation was observed), yet the presence 
of micelles at 12mM concentration appeared to negate the inhibition effect. SGC, STDC, and 
SGDC show comparable inhibition towards the combined kinetics at both aggregation levels. An 
increased in effectiveness of monomeric STC was observed compared to the growth only 
condition, suggesting impact on secondary nucleation.  
 To investigate the potential impact of monomeric bile salts on telaprevir secondary 
nucleation kinetics, the desupersaturation rate raito as a function of supersaturation is shown in 
Figure 7. For solutions with 1.86mM STC, the desupersaturation rate ratio increased with 
increasing supersaturation level. Meanwhile, desupersaturation was completely inhibited in the 
presence of monomeric STCDC at all supersaturation levels. These observations serve as 
evidence that monomeric STC and STCDC slow down telaprevir crystallization kinetics even 
when secondary nucleation takes place. This supposition is further supported by comparing the 
turbidity measurements at different supersaturation levels. While there appeared to be detectable 
secondary nucleation based on turbidity measurements for solutions in the absence of bile salts at 
higher supersaturation level (δ=7.9 and 12.5), there was no evidence for secondary nucleation for 
solutions in the presence of monomeric STC and STCDC. That is, these two bile salts appear to 
inhibit telaprevir secondary nucleation at 1.86mM concentration. 
Zeta potential measurements, an indication of electric potential difference at interfaces in 
solution, were conducted to understand the interactions of monomeric bile salts and the telaprevir 
crystals. In the literature, it is well known that adsorption (both physically and chemically) of 
ionized species can changes the measured zeta potential.
32
 
33
 Telaprevir is neutral, and 
monomeric bile salt is negatively charged in the buffer medium used in this study. Therefore, the 
change in zeta potential upon addition of monomeric bile salt serves as a qualitative indication of 
adsorption of bile salts at the telaprevir crystal interface. Figure 6 summarizes the zeta potential 
values of telaprevir crystals in the absence and presence of six monomeric level bile salts.  The 
zeta potential of telaprevir crystal in the absence of bile salts was -7.7 mV. A ~5-6 fold increase 
in the magnitude of zeta potential was observed with the addition of each of the six monomeric 
bile salts (1.86mM bile salt concentration), suggesting that bile salts interact with  telaprevir 
crystal surfaces. Although no direct correlation was observed between zeta-potential data and the 
extent of inhibition ability of bile salts, these results serve as evidence for bile salt interactions on 
telaprevir crystal surface. The growth inhibition mechanism of bile is not well understood, and 
there are very limited information in the literature. Mithani
34
 investigated the effect of STC on 
the crystal growth of dipyridamole using single crystal experiments. It was speculated that the 
adsorption of STC on the active growth sites leads to the growth inhibition of certain surface. 
With bulk crystal growth rate measurements and population balance modeling, Abbou Oucherif
35
 
showed that the growth mechanism of dipyridamole shifted from being mass transfer controlled 
to being a hybrid between mass transfer and surface integration controlled in the presence of 
2.2mM STC. More detailed studies are indeed required to fully explain the inhibition mechanism 
of bile salts. 
 In order to further confirm the inhibition ability of bile salts, residual supersaturation of 
the telaprevir solutions (δ=12.5) after 15 hour of crystallization was determined. By comparing 
Table 3 and Figure 5, the residual supersaturaiton is directly related to the effectiveness of bile 
salts (EC). With STC being the medium crystallization inhibitor, the majority of the initial 
provided supersaturation was consumed after 15 hours of crystallization. On the other hand, 
STCDC at 1.86mM concentration was able to maintain the supersaturation over 15 hours, while 
similar effect was not observed when bile salt concentration increased to 12mM. This 
observation further support our previous statement that monomeric STCDC is a highly effective 
inhibitor, for both crystal growth and secondary nucleation, for telaprevir. Since possible 
complexation can be form between SGCDC and telaprevir,[cite M#1] residual supersaturation 
was used to evaluate the effectiveness of SGCDC instead of using the desupersaturation method. 
As shown in Table 3, SGCDC shows similar behavior to STCDC. At 1.86mM SGCDC 
concentration, supersaturation was maintained over 15 hours. However, similar inhibition effect 
was not observed as SGCDC concentration increased to 12mM. By summarizing the 
observations, it is evident that monomeric STCDC and SGCDC are highly effective inhibitor for 
telaprevir crystal growth and secondary nucleation inhibitors. In addition, micelles of STCDC 
and SGCDC appear to negate the inhibitory impact of the monomers.  
Nucleation Inhibition Versus Growth Inhibition 
For system with additives, it is feasible to decouple the crystal growth effect from the 
measured nucleation induction time with proper experimental design and hence have a better 
understanding of nucleation kinetics.
28, 36
 In the previous study, we showed that unseeded 
supersaturated telaprevir solutions can be maintain to different extent in the presence of bile salts. 
However, we revealed that bile salts show different impact on crystal growth rates in the current 
study. That is, it is possible that the observed prolonged induction time was contributed by strong 
crystal growth inhibition. With the determining seedless induction times from the previous 
study[cite M#2] and the seeded desupersautration rates in the presence and absence of bile salts 
(Figure 5(b)) under similar experimental conditions, the relative nucleation rate in the presence 
and absence of the bile salt is estimated with the following equation: 
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!! (4) 
where J is the nucleation rate in the presence of bile salts, J0 is the nucleation rate in the absence 
of bile salts, R0/R is the desupersautration rate in the absence of bile salts divided by the rate in 
the presence of bile salts, tu,0 is the unseeded induction time in the absence of bile salts and tu is 
the induction time in the presence of bile salts. The effectiveness of bile salts in inhibiting 
nucleation EJ was further defined as below, and bile salts with EJ >1 were considered to be 
effective nucleation inhibitors. 
 !! !
!!
!
!! (5) 
For example, the induction time in the absence of bile salts was determined to be ~30 minutes 
and in the presence of monomeric bile salts the induction time was found to be more than 16 
hours (960 minutes was used in the calculation).[cite M#2] With the desupersautration rate ratios 
from Figure 5(b), EJ for monomeric bile salt, except STCDC and SGCDC, was then estimated to 
be around the range of 400-340,000,
 
much higher than the estimated values of EG (ranging 
between 1-3). That is to say, the ability of monomeric STC, SGC, STDC and SGDC to maintain 
supersaturation via growth inhibition is much weaker compared to their ability to inhibit 
nucleation. As for the extreme effective growth inhibitor, monomeric STCDC and SGCDC, there 
was no desupersautration observed during the experiments. By assuming EG to be 100, the EJ 
value estimated with Equation (4) and (5) is minimal, indicating that the prolonged induction 
time we observed in the previous study can be due the strong growth inhibition by STCDC and 
SGCDC. In other words, it is possible that nucleation did take place, but the nuclei were not able 
to grow to a detectable size due to monomeric STCDC and SGCDC blocking crystal growth.  It 
was reported in a previous nucleation induction time study that monomeric STCDC possesses 
the highest inhibitory effect for the three poorly soluble compounds, celecoxib, nevirapine, and 
flibanserin, compared to other 12 different bile salts.
13
 Based on our observations, growth 
inhibition can be a possible contributing factor. 
 Similar analysis was performed for bile salts at 12 mM, and Figure 8 summarized the 
inhibition ability of biorelevant bile salts at different aggregation levels. In general, we can 
categorize bile salts with some structural dependence. For trihydroxy bile salt STC and SGC, 
they exhibit strong ability in inhibiting telaprevir nucleation. As bile salt concentration increased 
to 12mM, the presence of micellar bile salts does not appeared to show significant impact on the 
inhibition ability (Figure 8(a)).   For STDC and SGDC, dihydroxy bile salt with the absence of 
hydroxyl group at R3 position on the steroid ring system, these bile salts appeared to be strong 
nucleation inhibitors for telaprevir at monomeric form. However, micelles of these dihydroxy 
bile salts appears to negate the inhibitory impact of the monomers(Figure 8(b)), which is 
consistent to our observation in the previous study.[cite M#2] For STCDC (and SGCDC), 
dihydroxy bile salt with the absence of hydroxyl group at R4 position on the steroid ring system, 
the monomeric form show extreme effectiveness in inhibiting telaprevir crystal growth. Similar 
to other dihydroxy bile salts, micelles of these dihydroxy bile salts appears to negate the 
inhibitory impact of the monomers(Figure 8(c)). 
Importance of Bile Salt Inhibition Properties. 
Due to the inevitable encounter of oral formulations with bile salts in biorelevant 
dissolution media and in vivo, understand the impact of bile salts on API crystallization has been 
a new area of research interest. For amorphous formulations, maintaining supersaturation for a 
biologically relevant time frame in the gastrointestinal tract is important for improved absorption. 
Although the composition varies from person to person, the bile salts investigated in this study 
are commonly found in human intestinal fluids.
37, 38
 It was demonstrated in the previous studies 
that bile salt significantly delayed crystallization of poorly soluble compounds from solution.
12, 
13
[cite M#2] However, their impact on crystal growth rate has not been considered. The presence 
of residual (seed) crystals is often unavoidable in an amorphous formulation due to its instable 
nature. The ability to control or slow down crystal growth significantly impact the degree of 
supersaturation available for absorption. Take telaprevir for example, supersaturation is possible 
to be maintained upon exposure in vivo, even with residual crystallinity present in the ASD, due 
to the crystal growth inhibition of the biorelevant bile salts. For polymer systems, it was reported 
that the extent of crystal growth inhibition can be improved through surface poisoning upon seed 
preparation.
23
 If similar mechanism applied, larger impact of bile salts on drug crystallization is 
expected if bile salts are employed as excipient in amorphous formulations.      
CONCLUSIONS 
In this study, the impact of six biologically relevant bile salts on desupersautration rate of 
seeded telaprevir solutions was evaluated at different bile salt aggregation levels. With the 
proposed in-situ common history seeding method, differences in the inhibitory ability of the bile 
salts were revealed. Most bile salts investigated slowed down telaprevir crystal growth. 
Monomeric STCDC and SGCDC were extremely effective growth inhibitors for telaprevir, and 
solution supersaturation was able to be maintained over time. However, the presence of the bile 
salt micelles opposed their monomeric inhibitory effect. In addition, Monomeric STC and 
STCDC were found to inhibit secondary nucleation of telaprevir at higher supersaturation levels. 
These observations of the endogenous bile salts provide the foundation for further studies on 
how biorelevant bile salt mixture impact the crystallization kinetics of drugs, which are crucial 
for better biopredictive dissolution media design and better in vivo behavior prediction of 
supersaturating systems.	 Lastly, bile salts are not interchangeable from a crystallization 
inhibition standpoint. 
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TABLES  
Table 1. Chemical structure of bile salts. 
R1	 R3	
R4	
R5	
	Bile salt Abbreviation R1 R3 R4 R5 
Sodium taurocholate STC OH OH OH NHCH2CH2SO3
-
 
Sodium taurodeoxycholate STDC OH H OH NHCH2CH2SO3
-
 
Sodium taurochenodeoxycholate STCDC OH OH H NHCH2CH2SO3
-
 
Sodium glycocholate SGC OH OH OH NHCH2COO
-
 
Sodium glycodeoxycholate SGDC OH H OH NHCH2COO
-
 
Sodium glycochenodeoxycholate SGCDC OH OH H NHCH2COO
-
 
 
 
 
Table 2. Supersaturation level for depsupersaturation experiments based on activity calibration. 
[citeM#1 and M#2] 
 
 
Table 3. Chemical structure of bile salts. 
 
Bile Salt Regenerated concentration 
for growth (µg/mL) 
Residual effective free drug 
concentration (µg/mL) 
1.86mM STC 65.2 9.0±1.8 
12mM STC 65.2 13.6±2.5 
1.86mM STCDC 65.2 60.5±6.9 
12mM STCDC 145.2 4.0±1.3 
1.86mM SGCDC 95.2 91.7±6.5 
12mM SGCDC 95.2 11.5±3.3 
Solution media Supersaturation ratio δ Regenerated concentration 
for growth (µg/mL) 
Buffer only, trihydroxy bile salts, 
and 1.86mM dihydroxy bile salts 
2.4 12.4 
12mM dihydroxy bile salt  20.2 
Buffer only, trihydroxy bile salts, 
and 1.86mM dihydroxy bile salts 
12.5 65.2 
12mM dihydroxy bile salt  145.2 
  
FIGURES  
	
	
Figure 1. Molecular structure of telaprevir.  
	
	
	
	
	
	
		
Figure 2. Experimental series for in-situ common history seeding method followed by 
desupersaturation rate and residual supersaturation measurements.  
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Figure 3. Rate of desupersaturation of telaprevir with seed crystals in the absence of bile salts at 
supersaturation ratios of 2.4 (red circles), 7.9(red triangles) and 12.5 (red crosses).  
	
	
	
Figure 4. SEM images of telaprevir crystals obtained from suppliers (upper row), and prepared 
from the in-situ common history seeding method (bottom row). 
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Figure 5. (a) Effectiveness as growth inhibitor of bile salts at an initial supersaturation level 
δ=2.4. (b) Effectiveness as crystallization inhibitor of bile salts at an initial supersaturation level 
δ=12.5. 
		
Figure 6. Zeta potential of telaprevir seed solution in the absence and presence of 1.86mM bile 
salts. 
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	Figure 7. Desupersaturation rate ratio of telaprevir at differernt supersaturation ratios in the 
presence of 1.86mM bile salt. 
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Figure 8. Effectiveness of bile salts as crystal growth inhibitor (EG) and nucleation inhibitor (EJ) 
for telaprevir crystallization: (a) trihydroxy bile salt STC and SGC (b) dihydroxy bile salt STDC 
and SGDC (c) trihydroxy bile salt STCDC.  
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